NCT06550765

Brief Summary

To verify and evaluate the safety and efficacy of biodegradable magnesium metal clips in the surgical margins of radical surgery for bone and soft tissue malignant tumors.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
98

participants targeted

Target at P50-P75 for not_applicable

Timeline
20mo left

Started Aug 2024

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress51%
Aug 2024Dec 2027

First Submitted

Initial submission to the registry

July 21, 2024

Completed
23 days until next milestone

First Posted

Study publicly available on registry

August 13, 2024

Completed
12 days until next milestone

Study Start

First participant enrolled

August 25, 2024

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2027

Expected
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2027

Last Updated

August 13, 2024

Status Verified

July 1, 2024

Enrollment Period

2.8 years

First QC Date

July 21, 2024

Last Update Submit

August 8, 2024

Conditions

Keywords

Soft Tissue sarcomabiodegradable magnesium metal

Outcome Measures

Primary Outcomes (2)

  • 1-year tumor recurrence rate

    Calculate the recurrence rate of the tumor one year after surgery.

    1 year

  • Total drainage volume

    Placement of a drainage tube in the surgical area, with postoperative drainage volumes recorded on the first, second, third, and fourth days.

    on the first, second, third, and fourth postoperative days.

Secondary Outcomes (4)

  • Blood magnesium ions levels

    at one month and six months after the operation

  • Serum alanine aminotransferase (ALT)

    at one month and six months after the operation

  • Serum creatinine

    at one month and six months after the operation

  • Estimated glomerular filtration rate (eGFR)

    at one month and six months after the operation

Study Arms (2)

Control group

NO INTERVENTION

The tumor lesion area is exposed using conventional surgery methods, and the tumor segment is resected according to the principles of tumor-free operation. Electrocautery and suture ligation are used to handle the tumor bleeding sites. The lesion area is thoroughly rinsed to ensure no active bleeding, and routine necessary reconstruction is performed.

Magnesium metal closure clips

EXPERIMENTAL

The tumor lesion area is exposed using conventional methods, and the tumor segment is resected according to the principles of tumor-free operation. Magnesium metal closure clips are used to clamp the tumor blood vessels, osteoperiosteal bleeding points, and other bleeding sites. The lesion area is thoroughly rinsed to ensure no active bleeding, and routine necessary reconstruction is performed.

Device: Biodegradable Magnesium Metal Clips

Interventions

The tumor lesion area is exposed using conventional methods, and the tumor segment is resected according to the principles of tumor-free operation. Magnesium metal closure clips are used to clamp the tumor blood vessels, osteoperiosteal bleeding points, and other bleeding sites. The lesion area is thoroughly rinsed to ensure no active bleeding, and routine necessary reconstruction is performed.

Magnesium metal closure clips

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Participants must be of either gender, aged between 18 and 65 years;
  • Diagnosis must be confirmed pathologically as osteosarcoma, synovial sarcoma, liposarcoma, or other bone and soft tissue sarcomas;
  • Must have undergone standard chemotherapy and require en bloc resection;
  • Participants must voluntarily enroll and sign an informed consent form; willing to closely cooperate with the physician to comply with all study requirements, including participation in all follow-up and assessments.

You may not qualify if:

  • Severe dysfunction of the heart, liver, kidney, lung, or brain.
  • Pregnant women or women who are breastfeeding.
  • History of autoimmune disease, HIV infection, history of immunosuppressive disorder, or currently taking immunosuppressive drugs.
  • History of syphilis (Treponema pallidum), active infection with hepatitis B or C, and positive for verified antigens.
  • Participation in any other clinical study currently or within 3 months prior to the screening visit.
  • Patients have any other conditions that the researcher deems unsuitable for the study. Age is between 18 to 75 years old.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Guangdong provincial people's hospital

Guangzhou, Guangdong, 516008, China

Location

MeSH Terms

Conditions

Sarcoma

Condition Hierarchy (Ancestors)

Neoplasms, Connective and Soft TissueNeoplasms by Histologic TypeNeoplasms

Central Study Contacts

Yu Zhang, Ph.D.

CONTACT

Yonghan Chen, Bachelor

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Experimental Group: The tumor lesion area is exposed using conventional methods, and the tumor segment is resected according to the principles of tumor-free operation. Magnesium metal closure clips are used to clamp the tumor blood vessels, osteoperiosteal bleeding points, and other bleeding sites. The lesion area is thoroughly rinsed to ensure no active bleeding, and routine necessary reconstruction is performed.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 21, 2024

First Posted

August 13, 2024

Study Start

August 25, 2024

Primary Completion (Estimated)

June 30, 2027

Study Completion (Estimated)

December 31, 2027

Last Updated

August 13, 2024

Record last verified: 2024-07

Data Sharing

IPD Sharing
Will not share

Researchers can request access from the corresponding author upon reasonable inquiry.

Locations